Adrenomyeloneuropathy Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics

Posted on
by

Adrenomyeloneuropathy Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics
The Key Adrenomyeloneuropathy Companies in the market include – Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others.

 

DelveInsight’s “Adrenomyeloneuropathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Adrenomyeloneuropathy, offering comprehensive insights into the Adrenomyeloneuropathy revenue trends, prevalence, and treatment landscape. The report delves into key Adrenomyeloneuropathy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Adrenomyeloneuropathy therapies. Additionally, we cover the landscape of Adrenomyeloneuropathy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Adrenomyeloneuropathy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Adrenomyeloneuropathy space.

 

To Know in detail about the Adrenomyeloneuropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Adrenomyeloneuropathy Market Forecast

 

Some of the key facts of the Adrenomyeloneuropathy Market Report:

  • The Adrenomyeloneuropathy market size was valued ~USD 9.26 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In December 2024, Bionomics Limited reported that favorable findings from its Phase 2 ATTUNE trial have been featured in NEJM Evidence. These results were also showcased at the 63rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in the event’s first-ever ‘Promising Targets’ session.

  • In October 2024, Spur Therapeutics revealed that preclinical proof-of-concept results for SBT101, its pioneering gene therapy for Adrenomyeloneuropathy, have been published in Molecular Therapy Methods & Clinical Development. The data further support SBT101’s promise as an innovative therapeutic approach for the condition.

  • In October 2024, Viking reported encouraging results from its Phase Ib study evaluating VK0214

  • Within the 7MM, the United States represented the biggest share of the Adrenomyeloneuropathy market, accounting for roughly 45% of the total.

  • Key Adrenomyeloneuropathy Companies: Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others

  • Key Adrenomyeloneuropathy Therapies: Leriglitazone (MIN-102), SBT101, VK0214, and others

  • The Adrenomyeloneuropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Adrenomyeloneuropathy pipeline products will significantly revolutionize the Adrenomyeloneuropathy market dynamics.

  • Although no therapies are currently approved for Adrenomyeloneuropathy, several mid- and late-stage pipeline candidates are showing promising potential. As per DelveInsight’s analysis, investigational treatments such as MIN-102 (Leriglitazone), SBT101, VK0214, and others are anticipated to drive major advancements in the coming years, offering renewed hope for meaningful therapeutic progress.

  • In 2024, the United States recorded approximately 1,000 diagnosed cases of Adrenomyeloneuropathy.

  • In 2024, Germany reported the largest number of diagnosed prevalent Adrenomyeloneuropathy cases among the EU4 and the UK, representing over 27% of the total.

  • In 2024, Japan recorded roughly 433 treated cases of Adrenomyeloneuropathy.

  • In 2024, there were an estimated 3,500 diagnosed prevalent cases of Adrenomyeloneuropathy across the 7MM, and this number is projected to rise by 2034.

 

Adrenomyeloneuropathy Overview

Adrenomyeloneuropathy (AMN) is a rare, inherited genetic disorder that primarily affects the spinal cord, peripheral nerves, and adrenal glands. It is a form of X-linked adrenoleukodystrophy (X-ALD) caused by mutations in the ABCD1 gene, leading to the buildup of very long-chain fatty acids (VLCFAs) in the body.

 

Get a Free sample for the Adrenomyeloneuropathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market

 

Adrenomyeloneuropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Adrenomyeloneuropathy Epidemiology Segmentation:

The Adrenomyeloneuropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Adrenomyeloneuropathy

  • Prevalent Cases of Adrenomyeloneuropathy by severity

  • Gender-specific Prevalence of Adrenomyeloneuropathy

  • Diagnosed Cases of Episodic and Chronic Adrenomyeloneuropathy

 

Download the report to understand which factors are driving Adrenomyeloneuropathy epidemiology trends @ Adrenomyeloneuropathy Epidemiology Forecast

 

Adrenomyeloneuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adrenomyeloneuropathy market or expected to get launched during the study period. The analysis covers Adrenomyeloneuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Adrenomyeloneuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Adrenomyeloneuropathy Therapies and Key Companies

  • Leriglitazone (MIN-102): Minoryx Therapeutics

  • SBT101: Spur Therapeutics

  • VK0214: Viking Therapeutics

 

Discover more about therapies set to grab major Adrenomyeloneuropathy market share @ Adrenomyeloneuropathy Treatment Landscape

 

Adrenomyeloneuropathy Market Drivers

  • Rising diagnosed prevalence across major markets, increasing the potential patient pool.

  • Growing awareness and improved genetic testing, enabling earlier and more accurate diagnosis of X-ALD and AMN.

  • Advancements in research and development, including gene therapies and novel small molecules showing promising clinical outcomes.

  • Increased investment by pharmaceutical companies driven by the unmet medical need and orphan drug incentives.

  • Supportive regulatory frameworks, such as fast-track and orphan drug designations, accelerating therapy development.

 

Adrenomyeloneuropathy Market Barriers

  • Lack of approved treatments, limiting therapeutic options and slowing market expansion.

  • Complex disease biology, making drug development challenging and time-consuming.

  • High cost of advanced therapies like gene therapy, potentially restricting accessibility.

  • Limited awareness in some regions, resulting in underdiagnosis or delayed diagnosis.

  • Small patient population, reducing commercial attractiveness and affecting investment in large-scale trials.

 

Scope of the Adrenomyeloneuropathy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Adrenomyeloneuropathy Companies: Minoryx Therapeutics, Spur Therapeutics, Viking Therapeutics, and others

  • Key Adrenomyeloneuropathy Therapies: Leriglitazone (MIN-102), SBT101, VK0214, and others

  • Adrenomyeloneuropathy Therapeutic Assessment: Adrenomyeloneuropathy current marketed and Adrenomyeloneuropathy emerging therapies

  • Adrenomyeloneuropathy Market Dynamics: Adrenomyeloneuropathy market drivers and Adrenomyeloneuropathy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Adrenomyeloneuropathy Unmet Needs, KOL’s views, Analyst’s views, Adrenomyeloneuropathy Market Access and Reimbursement

 

To know more about Adrenomyeloneuropathy companies working in the treatment market, visit @ Adrenomyeloneuropathy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Adrenomyeloneuropathy Market Report Introduction

2. Executive Summary for Adrenomyeloneuropathy

3. SWOT analysis of Adrenomyeloneuropathy

4. Adrenomyeloneuropathy Patient Share (%) Overview at a Glance

5. Adrenomyeloneuropathy Market Overview at a Glance

6. Adrenomyeloneuropathy Disease Background and Overview

7. Adrenomyeloneuropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Adrenomyeloneuropathy

9. Adrenomyeloneuropathy Current Treatment and Medical Practices

10. Adrenomyeloneuropathy Unmet Needs

11. Adrenomyeloneuropathy Emerging Therapies

12. Adrenomyeloneuropathy Market Outlook

13. Country-Wise Adrenomyeloneuropathy Market Analysis (2020–2034)

14. Adrenomyeloneuropathy Market Access and Reimbursement of Therapies

15. Adrenomyeloneuropathy Market Drivers

16. Adrenomyeloneuropathy Market Barriers

17. Adrenomyeloneuropathy Appendix

18. Adrenomyeloneuropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/